Article Data

  • Views 531
  • Dowloads 108

Editorials

Open Access

A comparative study of intensity-modulated radiotherapy and standard radiation field with concurrent chemotherapy for local advanced cervical cancer

  • C. Yu1,*,
  • W. Zhu1
  • Y. Ji1
  • J. Guo1
  • P. Pan1
  • J. Han1
  • X. Zhou1

1Department of Radiation Oncology, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an, Jiangsu Province, China

DOI: 10.12892/ejgo2622.2015 Vol.36,Issue 3,June 2015 pp.278-282

Published: 10 June 2015

*Corresponding Author(s): C. Yu E-mail: changhuyu@126.com

Abstract

Objective: This study aimed to compare three-dimensional conformal radiotherapy (3D CRT) and intensity-modulated radiotherapy (IMRT) combined with concurrent chemotherapy for cervical cancer. Materials and Methods: A total of 72 patients with Grades IIa–IIIb cervical cancer were randomly divided into two groups, namely, the IMRT group for IMRT plan (primary lesion, 45 Gy/22; the pelvic wall lymphatic drainage area, 50 Gy/22), and the 3D CRT group (conformal pelvic radiotherapy, 45 Gy/22; subsequent supplement of pelvic wall, 6.0 Gy/3). Both groups received concurrent chemotherapy of nedaplatin 30 mg/m2 weekly for six cycles, with an after-loading therapy of 6 Gy/6 each time. Results: In the IMRT group, the grade III diarrhea rate was 5.6% and the rate in the 3D CRT group was 30.6%; both groups significantly differed. No significant difference was observed between the overall survival and disease-free survival in first, second, and third years in both groups. Conclusion: Cervical cancer IMRT can significantly reduce the incidence of acute enteritis. For standard 3D CRT, no significant difference was observed in overall survival and disease-free survival.

Keywords

Cervical cancer; Three-dimensional conformal radiotherapy; Intensity-modulated radiotherapy; Efficacy.

Cite and Share

C. Yu,W. Zhu,Y. Ji,J. Guo,P. Pan,J. Han,X. Zhou. A comparative study of intensity-modulated radiotherapy and standard radiation field with concurrent chemotherapy for local advanced cervical cancer. European Journal of Gynaecological Oncology. 2015. 36(3);278-282.

References

[1] Portelance L., Chao K.S., Grigsby P.W., Bennet H., Low D.: “Intensity- modulated radiation therapy (IMRT) reduces small bowel, rectum, and bladder doses in patients with cervical cancer receiving pelvic and para-aortic irradiation”. Int. J. Radiat. Oncol. Biol. Phys., 2001, 51, 261.

[2] Heron D.E., Gerszten K., Selvaraj R.N., King G.C., Sonnik D., Gallion H. et al: “Conventional 3D conformal versus intensity-modulated radiotherapy for the adjuvant treatment of gynecologic malignancies: a comparative dosimetric study of dose-volume histograms small star, filled”. Gynecol. Oncol. 2003, 91, 39.

[3] D’Souza W.D., Ahamad A.A., Iyer R.B., Salehpour M.R., Jhingran A., Eifel P.J.: “Feasibility of dose escalation using intensity-modulated radiotherapy in posthysterectomy cervical carcinoma”. Int. J. Radiat. Oncol. Biol. Phys. 2005, 61, 1062.

[4] Green J.A., Kirwan J.M., Tierney J.F., Symonds P., Fresco L., Collingwood M. et al.: “Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis”. Lancet, 2001, 358, 781.

[5] Beriwal S., Gan G.N., Heron D.E., Selvaraj R.N., Kim H., Lalonde R. et al: “Early clinical outcome with concurrent chemotherapy and extended-field, intensity-modulated radiotherapy for cervical cancer”. Int. J. Radiat. Oncol. Biol. Phys., 2007, 68, 166.

[6] Folkert M.R., Shih K.K., Abu-Rustum N.R., Jewell E., Kollmeier M.A., Makker V. et al.: “Postoperative pelvic intensity-modulated radiotherapy and concurrent chemotherapy in intermediate - and high-risk cervical cancer”. Gynecol. Oncol., 2013,128, 288.

[7] Trotti A., Colevas A.D., Setser A., Rusch V., Jaques D., Budach V. et al.: “CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment”. Semin. Radiat. Oncol., 2003, 13, 176.

[8] Monk B.J., Tewari K.S., Koh W.J.: “Multimodality therapy for locally advanced cervical carcinoma: state of the art and future directions”. J. Clin. Oncol., 2007, 25, 2952.

[9] Song W.Y., Huh S.N., Liang Y., White G., Nichols R.C., Watkins W.T. et al.: “Dosimetric comparison study between intensity modulatedm radiation therapy and three-dimensional conformal proton therapy for pelvic bone marrow sparing in the treatment of cervical cancer”. J. Appl. Clin. Med. Phys., 2010, 11, 3255.

[10] Chen M.F., Tseng C.J., Tseng C.C., Yu C.Y., Wu C.T., Chen W.C.: “Adjuvant concurrent chemoradiotherapy with intensity-modulated pelvic radiotherapy after surgery for high-risk, early stage cervical cancer patients”. Cancer J., 2008, 14, 200.

[11] Kavanagh B.D., Schefter T.E., Wu Q., Tong S., Newman F., Arnfield M. et al.: “Clinical application of intensity-modulated radiotherapy for locally advanced cervical cancer”. Semin. Radiat. Oncol., 2002, 12, 260.

[12] Guerrero M., Li X.A., Ma L., Deyoung C., Erickson B.: “Simultaneous integrated intensity-modulated radiotherapy boost for locally advanced gynecological cancer: radiobiological and dosimetric considerations”. Int. J. Radiat. Oncol. Biol. Phys., 2005, 62, 933.

[13] Salama J.K., Mundt A.J., Roeske J., Mehta N.: “Preliminary outcome and toxicity report of extended-field, intensity-modulated radiation therapy for gynecologic malignancies”. Int. J. Radiat. Oncol. Biol. Phys., 2006, 65, 1170.

[14] Lai S.Z., Li W.F., Chen L., Luo W., Chen Y.Y., Liu L.Z. et al.: “How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients”? Int. J. Radiat. Oncol. Biol. Phys., 2011, 80, 661.

[15] Pearcey R., Miao Q., Kong W., Zhang-Salomons J., Mackillop W.J.: “Impact of adoption of chemoradiotherapy on the outcome of cervical cancer in Ontario: results of a population-based cohort study”. J. Clin. Oncol., 2007, 25, 2383.

[16] Vale C., Tierney J.F., Stewart L.A., Brady M., Dinshaw K., Jakobsen A. et al.: “Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials”. J. Clin. Oncol., 2008, 26, 5802.

[17] Chen M.F., Tseng C.J., Tseng C.C., Kuo Y.C., Yu C.Y., Chen W.C.: “Clinical outcome in posthysterectomy cervical cancer patients treated with concurrent Cisplatin and intensity-modulated pelvic radiotherapy: comparison with conventional radiotherapy”. Int. J. Radiat. Oncol. Biol. Phys., 2007, 67, 1438.

[18] Koshiyama M., Kinezaki M., Uchida T., Sumitomo M.: “Chemosensitivity testing of a novel platinum analog, nedaplatin (254-S), in human gynecological carcinomas: a comparison with cisplatin”. Anticancer Res., 2005, 25, 499.

[19] Moore K.N., Herzog T.J., Lewin S., Giuntoli R.L., Armstrong D.K., Rocconi R.P. et al.: “A comparison of cisplatin/paclitaxel and carboplatin/ paclitaxel in stage IVB, recurrent or persistent cervical cancer”. Gynecol. Oncol., 2007, 105, 299.

[20] Mollà M., Escude L., Nouet P., Popowski Y., Hidalgo A., Rouzaud M. et al.: “Fractionated stereotactic radiotherapy boost for gynecologic tumors: an alternative to brachytherapy”? Int. J. Radiat. Oncol. Biol. Phys., 2005, 62, 118.

[21] Grigsby P.W., Perez C.A., Chao K.S., Mutch D.G., Lockett M.A.: “Tumor size, irradiation dose, and long-term outcome of carcinoma of uterine cervix”. Int. J. Radiat. Oncol. Biol. Phys., 1998, 41, 307.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top